基于多组学分析探索胃瘤安合剂调控成纤维细胞亚群改善胃癌免疫微环境的机制

Multi-Omics Analysis of Wei-Liu-An Mixture in Modulating Fibroblast Subpopulations to Improve the Immune Microenvironment in Gastric Cancer

  • 摘要:
    目的 通过多组学整合分析,鉴定胃癌(Gastric cancer,GC)的免疫相关分型、预后生物标志物及潜在治疗靶点,并重点探讨中药复方胃瘤安合剂(简称“胃瘤安”)活性成分所介导的免疫调节机制。
    方法 基于免疫浸润特征,对胃癌患者队列进行无监督聚类,分为三种免疫表型:免疫“荒漠”型(Cluster 1)、免疫排斥型(Cluster 2)及免疫炎症型(Cluster 3)。随后采用差异表达分析筛选各免疫亚型间差异表达基因(Differentially expressed genes,DEGs),并将其与通过超高效液相色谱-串联质谱(Ultra-performance liquid chromatography-tandem mass spectrometry,UPLC-MS/MS)鉴定的胃瘤安代谢相关靶点进行交叉整合。进一步利用单细胞RNA测序(Single-cell RNA sequencing,scRNA-seq)数据,解析预后相关基因在肿瘤免疫微环境(Tumour immune microenvironment,TIME)不同细胞亚群中的表达及空间分布特征,重点对结晶蛋白αB(Crystallin alpha B,CRYAB)阳性成纤维细胞进行功能富集分析。在此基础上,我们构建免疫炎症亚型来源的九基因预后风险评分模型(Immune-Inflamed phenotype-derived 9-gene signature risk score,IIP-9GS),并在两个独立GC队列中进行外部验证,以评估其对患者生存风险分层的预测效能。
    结果 IIP-9GS预后风险评分模型能够有效区分GC患者的高、低风险人群,且在不同队列中表现出较为稳定的预后判别能力。其中,干扰素调节因子1(Interferon regulatory factor 1,IRF1)和干扰素γ(Interferon-gamma,IFNγ)不仅被鉴定为胃瘤安的潜在作用靶点,其高表达还与较优预后显著相关。相反,CRYAB在免疫炎症型Cluster 3中呈下调表达,而既往分析显示其高表达与预后不良密切相关,提示CRYAB可能是GC 中表征高危状态的关键基因。值得注意的是,CRYAB主要在成纤维细胞、平滑肌细胞和内皮细胞中高度富集,提示其可能通过调控肿瘤基质微环境发挥复杂的生物学作用。
    结论 本研究基于GC免疫浸润特征展开多组学整合的生物信息学分析,构建了IIP-9GS预后风险评分模型,并在单细胞水平发现CRYAB⁺成纤维细胞是TIME的关键基质调控节点,结合胃瘤安合剂活性成分的靶点预测结果,我们提出胃瘤安可能通过影响免疫相关通路及基质细胞状态参与TIME重塑,从而改善免疫抑制并缓解基质相关耐药。综上,CRYAB及其相关成纤维细胞亚群有望成为缓解免疫抑制、克服基质相关耐药的潜在治疗靶点,为GC中西医结合个体化治疗提供了新的研究线索与理论依据。

     

    Abstract:
    OBJECTIVE This study aims to identify immune-related subtypes, prognostic biomarkers and potential therapeutic targets in gastric cancer (GC) through integrative multi-omics analysis, with a particular focus on the immunoregulatory mechanisms mediated by the active components of the traditional Chinese herbal formula Wei-Liu-An Mixture (Wei-Liu-An-He-Ji, abbreviated as Wei-Liu-An).
    METHODS Based on immune infiltration profiles, unsupervised clustering was performed to stratify GC patients into three immune phenotypes: an immune-desert subtype (Cluster 1) , an immune-excluded subtype (Cluster 2) and an immune-inflamed subtype (Cluster 3). Differentially expressed genes (DEGs) among immune subtypes were identified and intersected with metabolite-related targets of Wei-Liu-An Mixture obtained by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Single-cell RNA sequencing (scRNA-seq) data were leveraged to delineate the cell-type-specific expression patterns and putative localization features of prognostic genes across distinct tumour immune microenvironment (TIME) compartments, with particular emphasis on functional enrichment analyses of crystallin alpha B (CRYAB)-positive fibroblasts. Finally, we developed an immune-inflamed subtype-derived 9-gene prognostic risk score model, termed IIP-9GS (Immune-Inflamed phenotype-derived 9-Gene Signature Risk Score), and externally validated its predictive performance for survival risk stratification in two independent GC cohorts.
    RESULTS The IIP-9GS prognostic risk score model effectively stratified patients with GC into high- and low-risk groups, demonstrating robust and stable discriminative performance across cohorts.Among the signature genes, interferon regulatory factor 1 (IRF1) and interferon-gamma (IFNG) were identified as potential targets of Wei-Liu-An, and their high expression was significantly associated with favorable prognosis. In contrast, CRYAB was downregulated in the immune-inflamed Cluster 3, whereas previous analyses indicated that its high expression correlated with poor survival, suggesting that CRYAB may represent a key high-risk gene in GC. Notably, CRYAB was highly enriched in fibroblasts, smooth muscle cells and endothelial cells, implying that it may exert complex biological effects by modulating the stromal compartment of the TIME.
    CONCLUSION The study performs multi-omics integrative bioinformatics analyses based on immune infiltration characteristics in gastric cancer (GC) and establishes the IIP-9GS prognostic risk score model. At the single-cell level, it suggests that CRYAB⁺ fibroblasts may represent a pivotal stromal regulatory node within the TIME. Integrating target prediction results for the active constituents of the Wei-Liu-An, we propose that Wei-Liu-An may contribute to TIME remodeling by modulating immune-related pathways and stromal cell states, thereby alleviating immunosuppression and mitigating stroma-associated resistance. Collectively, CRYAB and its associated fibroblast subpopulations may serve as potential prognostic biomarkers and therapeutic targets for overcoming immunosuppression and stroma-driven resistance, providing new clues and a theoretical basis for individualized integrative treatment strategies in GC.

     

/

返回文章
返回